EASL China Voice: DR10624 Phase II Results Show Significant Liver Fat Reduction and Metabolic Improvements in Severe Hypertriglyceridemia

Hepatology Digest recently provided an in-depth report on the research results presented by Doer Biologics at the EASL Congress 2026. 

The link to the report is provided below: https://mp.weixin.qq.com/s/kpKFjwA7HPR-0LBWa_v6Qg